Molecular therapy : the journal of the American Society of Gene TherapySep 14, 2025

Engineered immune cells targeting EGFRvIII for safer, more effective glioblastoma treatment

Gut-Brain Axis Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 2, 2026

Abstract

Allogeneic EGFRvIII-specific CAR-engineered invariant natural killer T (ECAR-NKT) cells show robust efficacy against glioblastoma in humanized models.

ECAR-NKT cells exhibit strong antitumor activity by directly killing tumor cells and targeting immunosuppressive cells in the tumor environment.
These cells are generated through a scalable platform using gene engineering of hematopoietic stem and progenitor cells.
In models of glioblastoma, ECAR-NKT cells display minimal systemic leakage from the brain, suggesting a localized therapeutic effect.
The treatment is associated with a reduced risk of cytokine release syndrome compared to traditional therapies.

Simplified

Glioblastoma (GBM) is the most aggressive and lethal primary brain tumor in adults, characterized by resistance to standard therapies, including surgical resection, radiation, chemotherapy, and targeted agents. While chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy has emerged as a promising immunotherapeutic approach for GBM, its application remains limited by tumor antigen escape, an immunosuppressive tumor microenvironment (TME), treatment-associated toxicities such as cytokine release syndrome (CRS), and the logistical complexities of autologous cell manufacturing. In this study, we leveraged hematopoietic stem and progenitor cell (HSPC) gene engineering combined with a feeder-free, ex vivo differentiation protocol to generate allogeneic EGFRvIII-specific CAR-engineered invariant natural killer T (ECAR-NKT) cells through a clinically guided, scalable platform. These cells exhibit potent, multifaceted antitumor activity against GBM, including direct tumor cell killing via CAR and NK receptors and selective targeting of CD1dimmunosuppressive cells within the TME via their invariant T cell receptors. In both subcutaneous and orthotopic GBM humanized models,ECAR-NKT cells demonstrated robust efficacy, minimal systemic leakage from the brain, and a reduced risk of CRS. Collectively, our findings supportECAR-NKT cells as a next-generation, off-the-shelf immunotherapy with enhanced efficacy and safety for the treatment of GBM. Allo + Allo Allo

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Engineered immune cells targeting EGFRvIII for safer, more effective glioblastoma treatment

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the gut-brain axis brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the gut-brain axis brief